Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, today announced that data from a clinical study of PRM-151 in patients with idiopathic pulmonary fibrosis (IPF) will be presented in an oral presentation at the 2013 American Thoracic Society (ATS) International Conference being held from May 17-22, 2013, in Philadelphia, Penn.
Help employers find you! Check out all the jobs and post your resume.
